Shares of Argos Therapeutics, Inc. (NASDAQ:ARGS) gapped up before the market opened on Thursday . The stock had previously closed at $0.24, but opened at $0.23. Argos Therapeutics shares last traded at $0.21, with a volume of 3,744,373 shares changing hands.

Separately, Zacks Investment Research cut shares of Argos Therapeutics from a “buy” rating to a “sell” rating in a research report on Monday, May 15th. One investment analyst has rated the stock with a sell rating and three have given a hold rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $3.23.

The firm has a 50 day moving average price of $0.24 and a 200-day moving average price of $0.52. The firm’s market cap is $11.38 million.

Argos Therapeutics (NASDAQ:ARGS) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.01. The firm had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.10 million. Argos Therapeutics had a negative net margin of 12,391.15% and a negative return on equity of 1,532.49%. Equities research analysts expect that Argos Therapeutics, Inc. will post ($1.14) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Argos Therapeutics, Inc. (ARGS) Shares Gap Up to $0.23” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.